Edgestream Partners L.P. Acquires 72,268 Shares of Insulet Corporation $PODD

Edgestream Partners L.P. acquired a new position in Insulet Corporation (NASDAQ:PODD – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 72,268 shares of the medical instruments supplier’s stock, valued at approximately $9,429,000.

Several other large investors also recently made changes to their positions in PODD. Elevation Wealth Partners LLC increased its stake in shares of Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 104 shares in the last quarter. Activest Wealth Management lifted its position in Insulet by 186.3% during the 3rd quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 149 shares in the last quarter. WPG Advisers LLC lifted its position in Insulet by 169.3% during the 3rd quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 171 shares in the last quarter. State of Wyoming lifted its position in Insulet by 34.6% during the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after buying an additional 73 shares in the last quarter. Finally, Continuum Advisory LLC bought a new stake in Insulet during the 2nd quarter worth about $46,000.

Analysts Set New Price Targets

PODD has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Insulet in a report on Monday, September 21st. Stifel Nicolaus dropped their target price on shares of Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Jefferies Financial Group reiterated a “buy” rating and set a $200.00 target price on shares of Insulet in a research report on Wednesday, November 4th. Benchmark reduced their target price on shares of Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, Robert W. Baird set a $175.00 price target on shares of Insulet in a research note on Thursday, August 6th. Twelve research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $185.67.

Read Our Latest Report on PODD

Insulet Stock Performance

Shares of Insulet stock opened at $145.34 on Wednesday. The firm has a fifty day moving average of $142.16 and a two-hundred day moving average of $172.43. The stock has a market capitalization of $10.08 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 1.11 and a beta of 1.06. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD – Get Free Report) last issued its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. The firm had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The company’s revenue was up 19.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.24 earnings per share. As a group, equities research analysts predict that Insulet Corporation will post 6.76 EPS for the current year.

About Insulet

(Free Report)

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Featured Articles

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.